Publicación:
Dinámica clínica, sociodemográfica y espacial de la infección por SARS-COV-2 en el departamento de Córdoba

Vista sencilla de ítem
dc.contributor.advisorSerrano Coll, Héctor Alejandro
dc.contributor.authorGaray, Evelin Montalvo
dc.contributor.refereeGuzmán Terán, Camilo
dc.contributor.refereeAndrés Felipe Diaz Delgadillo
dc.date.accessioned2021-07-08T22:33:15Z
dc.date.available2022-09-03
dc.date.available2021-07-08T22:33:15Z
dc.date.issued2021-07-07
dc.description.abstractThe serological evaluation of SARS-CoV-2 is an alternative that allows knowing the prevalence and dynamics of this infection in populations. Aim. To determine the clinical and socio-demographic dynamics of SARS-CoV-2 infection in a region of the Colombian Caribbean. Methods. Between July and November 2020, a cross-sectional observational study was carried out. The work was carried out in Córdoba, located in the northeast of Colombia in the Caribbean area. Eight municipalities with the largest population were chosen, and 2,564 blood samples were taken. The commercial ELISA was used with the recombinant protein antigen N of SARS-CoV-2. The people included in the study were asked for sociodemographic and clinical data related to pulmonary and extra-pulmonary manifestation of this disease, which were analyzed by statistical methods. Results. A seroposivity of 40.8% was obtained for SARS-CoV-2 in the Cordoba region of the Colombian Caribbean. In the bivariate analysis, no differences were observed in seropositivity against SARS-CoV-2 about gender or age range (P> 0.05). Higher seropositivity was found in low socioeconomic status and symptomatic patients (P <0.0001). 30.7% of the asymptomatic patients were seropositive for SARS-CoV-2, which would be linked to the spread of this infection. In the multivariate analysis, seroconversion was related to poverty and clinical manifestations such as anosmia and ageusia (P <0.05). Conclusions. The high seropositivity in the department of Córdoba would be related to a possible community immunity. Seropositivity would be related to clinical manifestations such as anosmia and ageusia. In addition, the association between seropositivity and socioeconomic level suggests an appropriate context for the transmission of the virus, this being determined by informal economic activities in low-income groups.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Microbiología Tropicalspa
dc.description.modalityTrabajo de Investigación y/o Extensiónspa
dc.description.resumenLa evaluación serológica del SARS-CoV-2 es una alternativa que permite conocer la prevalencia y dinámica de esta infección en poblaciones. Objetivo. Determinar la dinámica clínica y sociodemográfica de la infección por SARS-CoV-2 en una región del Caribe colombiano. Métodos. Entre julio y noviembre de 2020 se realizó un estudio observacional transversal. La investigación se llevó a cabo en Córdoba, ubicada en el noreste de Colombia en la zona del Caribe. Se eligieron ocho municipios con mayor población y se tomaron 2.564 muestras de sangre. El ELISA comercial se utilizó con el antígeno de proteína recombinante N de SARS-CoV-2. A las personas incluidas en el estudio se les solicitó datos sociodemográficos y clínicos relacionados a manifestaciones pulmonares y extrapulmonares de esta enfermedad, que fueron analizados por métodos estadísticos. Resultados. Se obtuvo una seropositividad del 40.8% para SARS-CoV-2 en la región de Córdoba del Caribe colombiano. En el análisis bivariado, no se observaron diferencias en la seropositividad frente al SARS-CoV-2 sobre el sexo o el rango de edad (P> 0,05). Se encontró una mayor seropositividad en el nivel socioeconómico bajo y en los pacientes sintomáticos (P <0,0001). El 30,7% de los pacientes asintomáticos fueron seropositivos para SARS-CoV-2, lo que estaría relacionado con la propagación de esta infección. En el análisis multivariado, la seroconversión se relacionó con la pobreza y manifestaciones clínicas como anosmia y ageusia (P <0,05). Conclusiones. La alta seropositividad en el departamento de Córdoba estaría relacionada con una posible inmunidad comunitaria. La seropositividad estaría relacionada con manifestaciones clínicas como anosmia y ageusia. Además, la asociación entre la seropositividad y el nivel socioeconómico permiten sugerir un contexto apropiado para la transmisión del virus, siendo este determinado por las actividades económicas informales en los grupos de bajos ingresos.spa
dc.description.tableofcontents1. RESUMEN ................................................................................................................................. 8spa
dc.description.tableofcontents2. ABSTRACT ............................................................................................................................... 9spa
dc.description.tableofcontents3. PLANTEAMIENTO DEL PROBLEMA .............................................................................. 10spa
dc.description.tableofcontents4. JUSTIFICACIÓN ................................................................................................................... 11spa
dc.description.tableofcontents5. PREGUNTA DE INVESTIGACIÓN .................................................................................... 12spa
dc.description.tableofcontents6. HIPÓTESIS. ............................................................................................................................ 12spa
dc.description.tableofcontents7. OBJETIVOS ............................................................................................................................ 12spa
dc.description.tableofcontents7.1 OBJETIVO GENERAL ................................................................................................. 12spa
dc.description.tableofcontents7.2 OBJETIVOS ESPECIFICOS: ............................................................................................. 12spa
dc.description.tableofcontents8. MARCO TEORICO ............................................................................................................... 13spa
dc.description.tableofcontents8.1 SÍNDROME RESPIRATORIO AGUDO GRAVE DE TIPO 2 (SARS-CoV-2) ................ 13spa
dc.description.tableofcontents8.2 ESTRUCTURA DE LOS CORONAVIRUS ....................................................................... 14spa
dc.description.tableofcontents8.3 EPIDEMIOLOGIA ............................................................................................................... 16spa
dc.description.tableofcontents8.3.1 Factor Ro del SARS – CoV-2 ........................................................................................ 16spa
dc.description.tableofcontents8.3.2 Distribución de casos por edades .................................................................................. 17spa
dc.description.tableofcontents8.3.3 MECANISMOS DE TRANSMISIÓN .......................................................................... 18spa
dc.description.tableofcontents8.4 RESPUESTA INMUNE DE LA INFECCIÓN POR SARS-CoV-2 .................................. 18spa
dc.description.tableofcontents8.5 MANIFESTACIONES Y DATOS CLÍNICOS .................................................................. 20spa
dc.description.tableofcontents8.6 PRUEBAS DIAGNOSTICAS PARA LA INFECCIÓN POR SARS-COV 2 .................. 21spa
dc.description.tableofcontents8.7 VARIANTES GÉNETICAS DEL SARS-CoV-2 ................................................................ 22spa
dc.description.tableofcontents8.8 TRATAMIENTOS CONTRA EL SARS-CoV-2 ................................................................ 23spa
dc.description.tableofcontents9. MÉTODOS. ............................................................................................................................. 25spa
dc.description.tableofcontents9.1 Tipo de estudio ................................................................................................................. 25spa
dc.description.tableofcontents9.2 Cálculo del tamaño de la muestra y distribución. ........................................................ 25spa
dc.description.tableofcontents9.3 Criterios de inclusión y exclusión .................................................................................. 25spa
dc.description.tableofcontents9.4 Recolección de muestras. ................................................................................................ 26spa
dc.description.tableofcontents9.5 Descripción de las variables ................................................................................................. 26spa
dc.description.tableofcontents9.5.1 Diagrama de las variables .............................................................................................. 27spa
dc.description.tableofcontents9.6 Técnicas y procedimientos. .................................................................................................. 28spa
dc.description.tableofcontents9.6.1 Recolección de la información. ..................................................................................... 28spa
dc.description.tableofcontents9.7 Fuentes de información. ....................................................................................................... 29spa
dc.description.tableofcontents9.8 Actividades. ............................................................................................................................ 29spa
dc.description.tableofcontents9.8.1 Actividades desarrolladas para dar cumplimiento al objetivo 1: .............................. 29spa
dc.description.tableofcontents9.8.2 Actividades desarrolladas para dar cumplimiento al objetivo 2: .............................. 30spa
dc.description.tableofcontents9.8.3 Actividades desarrolladas para dar cumplimiento al objetivo 3: .............................. 31spa
dc.description.tableofcontents9.8.4 Actividades desarrolladas para dar cumplimiento al objetivo 4: ............................. 31spa
dc.description.tableofcontents9.8.5 Actividades desarrolladas para dar cumplimiento al objetivo 5: .............................. 32spa
dc.description.tableofcontents9.9 Análisis de los datos............................................................................................................... 32spa
dc.description.tableofcontents9.10 Consideraciones éticas ........................................................................................................ 32spa
dc.description.tableofcontents10. RESULTADOS .................................................................................................................... 33spa
dc.description.tableofcontents10.1 Características socio-demográficas y clínicas de la población muestreada. .............. 33spa
dc.description.tableofcontents10.2 Dinámica espacial de la infección por SARS-CoV-2 en los municipios evaluados. ... 34spa
dc.description.tableofcontents10.3 Relación las características sociodemográficas (rango etario, género, estrato socioeconómico) con la frecuencia de infección por SARS-CoV-2. ........................................ 38spa
dc.description.tableofcontents10.3 Dinámica clínica y su relación con la seropositividad por SARS-CoV-2. .................. 40spa
dc.description.tableofcontents10.4 Modelo explicativo para la dinámica en la infección por SARS-CoV-2 en los municipios evaluados en el departamento de Córdoba. .......................................................... 41spa
dc.description.tableofcontents11. DISCUSIÓN ......................................................................................................................... 43spa
dc.description.tableofcontents11.1 Dinámica espacial de la infección por SARS-CoV-2 en los municipios evaluados ........ 43spa
dc.description.tableofcontents11.2 Relación de las características sociodemográficas (rango etario, género, estrato socioeconómico) con la frecuencia de infección por SARS-CoV-2. ........................................ 45spa
dc.description.tableofcontents11.3 Dinámica clínica y su relación con la seropositividad por SARS-CoV-2. ...................... 47spa
dc.description.tableofcontents11.4 Modelo explicativo para la dinámica en la infección por SARS-CoV-2 en los municipios evaluados en el departamento de Córdoba. .............................................................................. 47spa
dc.description.tableofcontents12. CONCLUSIONES Y RECOMENDACIONES ................................................................ 48spa
dc.description.tableofcontents13. LIMITACIONES ................................................................................................................ 49spa
dc.description.tableofcontents14. BIBLIOGRÁFIA ................................................................................................................. 50spa
dc.description.tableofcontents15. ANEXOS .............................................................................................................................. 63spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.urihttps://repositorio.unicordoba.edu.co/handle/ucordoba/4257
dc.language.isospaspa
dc.publisherInstituto de Investigaciones Biológicas del Trópico (Unicordoba) - Mincienciasspa
dc.publisher.facultyFacultad de Medicina Veterinaria y Zootecniaspa
dc.publisher.placeMontería, Córdoba, Colombiaspa
dc.publisher.programMaestría en Microbiología Tropicalspa
dc.rightsCopyright Universidad de Córdoba, 2021spa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.keywordsPublic healtheng
dc.subject.keywordsAsymptomaticeng
dc.subject.keywordsSeroepidemiologic studieseng
dc.subject.keywordsSocial conditionseng
dc.subject.keywordsEconomic conditionseng
dc.subject.keywordsInformal social controlseng
dc.subject.proposalSalud públicaspa
dc.subject.proposalAsintomáticosspa
dc.subject.proposalEstudios seroepidemiológicospa
dc.subject.proposalCondiciones socialesspa
dc.subject.proposalControles sociales informalesspa
dc.titleDinámica clínica, sociodemográfica y espacial de la infección por SARS-COV-2 en el departamento de Córdobaspa
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/submittedVersionspa
dcterms.references1. Reina J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundo. Vacunas. 2020;spa
dcterms.references2. Huang Q, Wu X, Zheng X, Luo S, Xu S, Weng J. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res [Internet]. 2020/06/27. 2020 Sep;159:105051. Available from: https://pubmed.ncbi.nlm.nih.gov/32603772spa
dcterms.references3. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care [Internet]. 2020;24(1):179. Available from: https://doi.org/10.1186/s13054-020-02902-wspa
dcterms.references4. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care [Internet]. 2020;24(1):108. Available from: https://doi.org/10.1186/s13054-020-2833-7spa
dcterms.references5. Peters A, Vetter P, Guitart C, Lotfinejad N, Pittet D. Understanding the emerging coronavirus: what it means for health security and infection prevention. J Hosp Infect [Internet]. 2020/03/05. 2020 Apr;104(4):440–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32145323spa
dcterms.references6. DEAGO DE LEÓN EM, ROZO GARCÉS ND, RODRÍGUEZ MIRANDA JP. SARS-CoV2 en países tropicales: interacción epidemiológica, ambiental y económica, estudio de caso Colombia (Sudamérica). Rev Espac ISSN. 798:1015.spa
dcterms.references7. Neilan AM, Losina E, Bangs AC, Flanagan C, Panella C, Eskibozkurt GE, et al. Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts. medRxiv Prepr Serv Heal Sci [Internet]. 2020 Jul 24;2020.07.23.20160820. Available from: https://pubmed.ncbi.nlm.nih.gov/32743604spa
dcterms.references8. Ena J, Wenzel RP. A Novel Coronavirus Emerges TT - Un nuevo coronavirus emerge. Rev Clin Esp [Internet]. 2020 Mar;220(2):115–6. Available from: https://pubmed.ncbi.nlm.nih.gov/32063263spa
dcterms.references9. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al. Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2. Ann Intern Med [Internet]. 2020 Jun 4;173(6):450–60. Available from: https://doi.org/10.7326/M20-2854spa
dcterms.references10. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science (80- ) [Internet]. 2020 Jul 10;369(6500):208 LP – 211. Available from: http://science.sciencemag.org/content/369/6500/208.abstractspa
dcterms.references11. Greenaway C, Dongier P, Boivin J-F, Tapiero B, Miller M, Schwartzman K. Susceptibility to Measles, Mumps, and Rubella in Newly Arrived Adult Immigrants and Refugees. Ann Intern Med [Internet]. 2007 Jan 2;146(1):20–4. Available from: https://www.acpjournals.org/doi/abs/10.7326/0003-4819-146-1-200701020-00005spa
dcterms.references12. Eiros Bouzaa José M., Oteo Revueltab JA. Enfermedades infecciosas zoonóticas. Enferm Infecc Microbiol Clin [Internet]. 2011;29(Supl 3):51–4. Available from: https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-pdf-S0213005X11700283spa
dcterms.references13. Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol [Internet]. 2020;92(4):401–2. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25678spa
dcterms.references14. Ye Z-W, Yuan S, Yuen K-S, Fung S-Y, Chan C-P, Jin D-Y. Zoonotic origins of human coronaviruses. Int J Biol Sci [Internet]. 2020 Mar 15;16(10):1686–97. Available from: https://pubmed.ncbi.nlm.nih.gov/32226286spa
dcterms.references15. Martínez Chamorro E, Díez Tascón A, Ibáñez Sanz L, Ossaba Vélez S, Borruel Nacenta S. Diagnóstico radiológico del paciente con COVID-19. Radiologia [Internet]. 2021;63(1):56–73. Available from: https://www.sciencedirect.com/science/article/pii/S003383382030165Xspa
dcterms.references16. Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clin Imaging [Internet]. 2020;66:35–41. Available from: http://www.sciencedirect.com/science/article/pii/S0899707120301674spa
dcterms.references17. Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier HJ, Bickerton E, Britton P, editors. Coronaviruses: Methods and Protocols [Internet]. New York, NY: Springer New York; 2015. p. 1–23. Available from: https://doi.org/10.1007/978-1-4939-2438-7_1spa
dcterms.references18. Centro para el control y prevención de enfermedades CDC. Micrositio sobre el COVID-19 [Internet]. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/communication/index-sp.htmlspa
dcterms.references19. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164.spa
dcterms.references20. Chen YL. Q., Guo, D.(2020) Emerging coronaviruses: Genome structure, replication, parthenogenesis. J Virol. 92:418423.spa
dcterms.references21. Bosch BJ, van der Zee R, de Haan CAM, Rottier PJM. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol [Internet]. 2003 Aug;77(16):8801–11. Available from: https://pubmed.ncbi.nlm.nih.gov/12885899spa
dcterms.references22. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;spa
dcterms.references23. Salud OP de la. La OMS caracteriza a COVID-19 como una pandemia [Internet]. [cited 2021 Jan 19]. Available from: https://www.paho.org/es/noticias/11-3-2020-oms-caracteriza-covid-19-como-pandemia#:~:text=Ginebra%2C 11 de marzo de,puede caracterizarse como una pandemia.spa
dcterms.references24. Organization WH. Coronavirus Disease (COVID-19) Dashboard [Internet]. 2020 [cited 2021 Mar 3]. Available from: https://covid19.who.int/spa
dcterms.references25. Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, et al. Epidemiology of SARS-CoV-2. Infection [Internet]. 2020; Available from: https://doi.org/10.1007/s15010-020-01531-3spa
dcterms.references26. Ridenhour B, Kowalik JM, Shay DK. El número reproductivo básico (R0): consideraciones para su aplicación en la salud pública. Rev Panam Salud Pública. 2015;38:167–76.spa
dcterms.references27. Rocklöv J, Sjödin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. J Travel Med [Internet]. 2020 May 18;27(3). Available from: https://doi.org/10.1093/jtm/taaa030spa
dcterms.references28. Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA [Internet]. 2020 Feb 25;323(8):707–8. Available from: https://doi.org/10.1001/jama.2020.0757spa
dcterms.references29. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med [Internet]. 2020;172(9):577–82. Available from: https://doi.org/10.7326/M20-0504spa
dcterms.references30. Immunologie R und I für die, Molekularbiologie Z und. SARS-CoV-2 (Covid-19): Diagnosis by IgG/IgM Rapid Test [Internet]. [cited 2021 Apr 14]. Available from: https://www.biotrend.com/lesen/newsletter-26/sars-cov-2-covid-19-diagnosis-by-2264.htmlspa
dcterms.references31. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi. 2020;41(2):145.spa
dcterms.references32. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020. Eurosurveillance. 2020;25(31):2001383.spa
dcterms.references33. Institute RK. Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute [Internet]. GERMANY; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Maerz_2021/2021-03-02-en.pdf?__blob=publicationFilespa
dcterms.references34. zur Coronavirus RKIT des RKI. Krankheit-2019 (COVID-19) 25.08. 2020–AKTUALISIERTER STAND FÜR DEUTSCHLAND. Berlin: Robert-Koch-Institut2020. 2020;25.spa
dcterms.references35. Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building. Ann Intern Med [Internet]. 2020;173(12):974–80. Available from: https://doi.org/10.7326/M20-0928spa
dcterms.references36. Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int [Internet]. 2020/04/10. 2020 Jun;139:105730. Available from: https://pubmed.ncbi.nlm.nih.gov/32294574spa
dcterms.references37. van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Ther [Internet]. 2020 Oct 1;52(8):1276–88. Available from: https://doi.org/10.1111/apt.16036spa
dcterms.references38. Mattar S, Martinez-Bravo C, Rivero R, Contreras H, Faccini-Martínez ÁA, Guzman-Teran C, et al. Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean. Ann Clin Microbiol Antimicrob. 2020;19(1):1–6.spa
dcterms.references39. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Nature Publishing Group; 2020.spa
dcterms.references40. Lozada-Requena I, Núñez Ponce C. COVID-19: respuesta inmune y perspectivas terapéuticas. Rev Peru Med Exp Salud Publica. 2020;37:312–9.spa
dcterms.references41. Leo O, Cunningham A, Stern PL. Vaccine immunology. Perspect Vaccinol. 2011;1(1):25–59.spa
dcterms.references42. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.spa
dcterms.references43. Bwire GM. Coronavirus: why men are more vulnerable to Covid-19 than women? SN Compr Clin Med. 2020;2(7):874–6.spa
dcterms.references44. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730–41.spa
dcterms.references45. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [Internet]. 2020;8(5):475–81. Available from: http://www.sciencedirect.com/science/article/pii/S2213260020300795spa
dcterms.references46. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current State of the Science. Immunity [Internet]. 2020;52(6):910–41. Available from: http://www.sciencedirect.com/science/article/pii/S1074761320301837spa
dcterms.references47. Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol [Internet]. 2020;31(5):454–70. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/pai.13271spa
dcterms.references48. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell [Internet]. 2021; Available from: https://www.sciencedirect.com/science/article/pii/S0092867421000076spa
dcterms.references49. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020 Feb 15;395(10223):497–506. Available from: https://doi.org/10.1016/S0140-6736(20)30183-5spa
dcterms.references50. Vaira LA, Salzano G, Fois AG, Piombino P, De Riu G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy Rhinol [Internet]. 2020 Sep 1;10(9):1103–4. Available from: https://doi.org/10.1002/alr.22593spa
dcterms.references51. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. Int J Infect Dis. 2020;spa
dcterms.references52. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med [Internet]. 2020 Apr 17;382(24):2372–4. Available from: https://doi.org/10.1056/NEJMc2010419spa
dcterms.references53. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA [Internet]. 2020 Apr 21;323(15):1488–94. Available from: https://doi.org/10.1001/jama.2020.3204spa
dcterms.references54. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol [Internet]. 2020 Oct 1;92(10):1902–14. Available from: https://doi.org/10.1002/jmv.25884spa
dcterms.references55. Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One [Internet]. 2020 Jul 9;15(7):e0235458. Available from: https://doi.org/10.1371/journal.pone.0235458spa
dcterms.references56. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2020;1–13.spa
dcterms.references57. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, et al. Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clin Microbiol Infect [Internet]. 2020;26(9):1178–82. Available from: https://www.sciencedirect.com/science/article/pii/S1198743X20303633spa
dcterms.references58. Swedish Public Health Agency. Initial results from ongoing investigation of antibodies to covid-19 virus. [Internet]. 2020. Available from: https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus/spa
dcterms.references59. Caini S, Bellerba F, Corso F, Díaz-Basabe A, Natoli G, Paget J, et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Eurosurveillance [Internet]. 2020;25(23). Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.23.2000980spa
dcterms.references60. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect [Internet]. 2020;26(8):1082–7. Available from: https://www.sciencedirect.com/science/article/pii/S1198743X20303001spa
dcterms.references61. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv [Internet]. 2020 Jan 1;2020.03.24.20042382. Available from: http://medrxiv.org/content/early/2020/03/26/2020.03.24.20042382.abstractspa
dcterms.references62. OMS. Directrices de Laboratorio para la Detección y el Diagnóstico de la Infección con el Virus COVID-19, 30 de marzo de 2020 [Internet]. 2020. Available from: https://iris.paho.org/bitstream/handle/10665.2/52370/OPSPHEIMSCOVID-19200003_spa.pdf?sequence=1&isAllowed=yspa
dcterms.references63. Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;115094.spa
dcterms.references64. US Centers for Disease Control and Prevention (CDC). SARS-CoV-2 Variant Classifications and Definitions [Internet]. Mar. 16, 2021; Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.htmlspa
dcterms.references65. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv [Internet]. 2021 Jan 1;2021.01.27.428516. Available from: http://biorxiv.org/content/early/2021/01/29/2021.01.27.428516.abstractspa
dcterms.references66. Wang P, Wang M, Yu J, Cerutti G, Nair MS, Huang Y, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv [Internet]. 2021 Jan 1;2021.03.01.433466. Available from: http://biorxiv.org/content/early/2021/03/02/2021.03.01.433466.abstractspa
dcterms.references67. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care [Internet]. 2020;24(1):91. Available from: https://doi.org/10.1186/s13054-020-2818-6spa
dcterms.references68. García-Salido A. Revisión narrativa sobre la respuesta inmunitaria frente a coronavirus: descripción general, aplicabilidad para SARS-COV-2 e implicaciones terapéuticas. An Pediatría [Internet]. 2020;93(1):60.e1-60.e7. Available from: https://www.sciencedirect.com/science/article/pii/S1695403320301727spa
dcterms.references69. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med [Internet]. 2020 Mar 18;382(19):1787–99. Available from: https://doi.org/10.1056/NEJMoa2001282spa
dcterms.references70. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax [Internet]. 2004 Mar 1;59(3):252 LP – 256. Available from: http://thorax.bmj.com/content/59/3/252.abstractspa
dcterms.references71. Ko W-C, Rolain J-M, Lee N-Y, Chen P-L, Huang C-T, Lee P-I, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents [Internet]. 2020/03/06. 2020 Apr;55(4):105933. Available from: https://pubmed.ncbi.nlm.nih.gov/32147516spa
dcterms.references72. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res [Internet]. 2020;30(3):269–71. Available from: https://doi.org/10.1038/s41422-020-0282-0spa
dcterms.references73. Cedeño KSM. Mecanismos propuestos de los macrólidos. Efectos inmunomoduladores y anti-inflamatorios en enfermedades respiratorias. Vitae. 2019;(77).spa
dcterms.references74. China Seeks Plasma From Recovered Patients to Treat Virus | Time [Internet]. [cited 2021 Mar 3]. Available from: https://time.com/5784286/covid-19-china-plasma-treatment/spa
dcterms.references75. World Health Organization Coronavirus disease. Protocolo para estudios seroepidemiológicos poblacionales sobre la COVID-19, con estratificación por edades [Internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigationsspa
dcterms.references76. Franco R, Hopenhayn M, León A. The growing and changing middle class in Latin America: an update. Cepal Rev. 2011;spa
dcterms.references77. Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty [Internet]. 2020;9(1):29. Available from: https://doi.org/10.1186/s40249-020-00646-xspa
dcterms.references78. Eurofins Technologies. INgezim COVID 19 DR [Internet]. 2020. Available from: https://ingenasa.eurofins-technologies.com/home-es/productos/covid19/ensayo-elisa/ingezim-covid-19-dr/spa
dcterms.references79. Rubin D, Huang J, Fisher BT, Gasparrini A, Tam V, Song L, et al. Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. JAMA Netw Open [Internet]. 2020 Jul 23;3(7):e2016099–e2016099. Available from: https://doi.org/10.1001/jamanetworkopen.2020.16099spa
dcterms.references80. Ramírez JD, Florez C, Muñoz M, Hernández C, Castillo A, Gomez S, et al. The arrival and spread of SARS-CoV-2 in Colombia. J Med Virol [Internet]. 2021;93(2):1158–63. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26393spa
dcterms.references81. Ariza B, Torres X, Salgado D, Cepeda M, Restrepo CG, Castellanos JC, et al. Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogotá, Colombia. Infectio. 2021;25(3):145–52.spa
dcterms.references82. Idrovo ÁJ, Moreno-Montoya J, Pinzón-Flórez CE. Desempeño de las pruebas combinadas de IgM e IgG rápidas en la vigilancia ocupacional de COVID-19 en empresas colombianas. Biomédica. 2020;40:139–47.spa
dcterms.references83. Malagón-Rojas JN, Rubio V, Parra-Barrera E. Seroprevalence and seroconversions for SARS-CoV-2 infections in workers at Bogota Airport, Colombia, 2020. J Travel Med [Internet]. 2021 Jan 22; Available from: https://doi.org/10.1093/jtm/taab006spa
dcterms.references84. Buss LF, Prete Jr CA, Abrahim CMM, Mendrone Jr A, Salomon T, de Almeida-Neto C, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science [Internet]. 2020/12/08. 2021 Jan 15;371(6526):288–92. Available from: https://pubmed.ncbi.nlm.nih.gov/33293339spa
dcterms.references85. Slute M della. Covid-19, illustrati i risultati dell’indagine di sieroprevalenza [Internet]. Italy; Available from: http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=4998spa
dcterms.references86. Zyskind I, Rosenberg AZ, Zimmerman J, Naiditch H, Glatt AE, Pinter A, et al. SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States. JAMA Netw Open [Internet]. 2021 Mar 10;4(3):e212816–e212816. Available from: https://doi.org/10.1001/jamanetworkopen.2021.2816spa
dcterms.references87. Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. J Med Virol [Internet]. 2020;92(10):1795–6. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25904spa
dcterms.references88. Song S-K, Lee D-H, Nam J-H, Kim K-T, Do J-S, Kang D-W, et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea. J Korean Med Sci [Internet]. 2020 Jul;35(29). Available from: https://doi.org/10.3346/jkms.2020.35.e269spa
dcterms.references89. Faccini-Mart\’\inez ÁA, Rivero R, Garay E, Garc\’\ia A, Mattar S, Botero Y, et al. Serological cross-reactivity using a {SARS}-{CoV}-2 {ELISA} test in acute Zika virus infection, Colombia. Int J Infect Dis [Internet]. 2020;101:191–3. Available from: https://doi.org/10.1016%2Fj.ijid.2020.09.1451spa
dcterms.references90. Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, Martel KS, Valle A, Valverde J, et al. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru. EClinicalMedicine. 2021;34:100801.spa
dcterms.references91. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet (London, England) [Internet]. 2020/06/11. 2020 Aug 1;396(10247):313–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32534626spa
dcterms.references92. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;1–3.spa
dcterms.references93. Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020;spa
dcterms.references94. Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko A, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. medRxiv. 2020;spa
dcterms.references95. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngology. 2020;1–11.spa
dcterms.references96. Bampoe S, Lucas DN, Neall G, Sceales P, Aggarwal R, Caulfield K, et al. A cross‐sectional study of immune seroconversion to SARS‐CoV‐2 in frontline maternity health professionals. Anaesthesia. 2020;75(12):1614–9.spa
dcterms.references97. Paolo C, Carmelo S, Marcello M. Ageusia, gastrointestinal symptoms and marked asthenia in late December. A single case report with positive SARS-Cov2 IgG in Italy. Int J Infect Dis. 2020;97:352–3.spa
dcterms.references98. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. Laryngoscope [Internet]. 2020 Jul 1;130(7):1787. Available from: https://doi.org/10.1002/lary.28692spa
dcterms.references99. Lechner M, Chandrasekharan D, Jumani K, Liu J, Gane S, Lund VJ, Philpott C JS. Anosmia as a presenting symptom of SARS-CoV-2 infection in healthcare workers - A systematic review of the literature, case series, and recommendations for clinical assessment and management. Natl Libr Med Pubmed [Internet]. :58(4):394-399. Available from: https://pubmed.ncbi.nlm.nih.gov/32386285/spa
dcterms.references100. Vargas-Gandica J, Winter D, Schnippe R, Rodriguez-Morales AG, Mondragon J, Escalera-Antezana JP, et al. Ageusia and anosmia, a common sign of COVID-19? A case series from four countries. J Neurovirol [Internet]. 2020;26(5):785–9. Available from: https://doi.org/10.1007/s13365-020-00875-8spa
dcterms.references101. National Statistical Office of England. Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19 in England [Internet]. 27 January 2021; Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021#symptoms-profile-by-cases-comspa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_f1cfspa
oaire.versionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
Archivos
Bloque original
Mostrando 1 - 2 de 2
Miniatura
Nombre:
Garay, Evelin Montalvo.pdf
Tamaño:
1.77 MB
Formato:
Adobe Portable Document Format
Descripción:
Trabajo de grado
Descargar
No hay miniatura disponible
Nombre:
Formato_Autorización.pdf
Tamaño:
2.21 MB
Formato:
Adobe Portable Document Format
Descripción:
Autorización de Tesis
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
14.48 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
G.D.A. Tesis